Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.28
NVSEF's Cash-to-Debt is ranked lower than
82% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. NVSEF: 0.28 )
Ranked among companies with meaningful Cash-to-Debt only.
NVSEF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 1.05 Max: 3.39
Current: 0.28
0.18
3.39
Equity-to-Asset 0.52
NVSEF's Equity-to-Asset is ranked lower than
67% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NVSEF: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
NVSEF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.58 Max: 0.65
Current: 0.52
0.51
0.65
Debt-to-Equity 0.44
NVSEF's Debt-to-Equity is ranked lower than
61% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. NVSEF: 0.44 )
Ranked among companies with meaningful Debt-to-Equity only.
NVSEF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12  Med: 0.26 Max: 0.48
Current: 0.44
0.12
0.48
Debt-to-EBITDA 2.32
NVSEF's Debt-to-EBITDA is ranked lower than
59% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. NVSEF: 2.32 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NVSEF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.55  Med: 1.61 Max: 2.79
Current: 2.32
0.55
2.79
Interest Coverage 11.07
NVSEF's Interest Coverage is ranked lower than
72% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 106.84 vs. NVSEF: 11.07 )
Ranked among companies with meaningful Interest Coverage only.
NVSEF' s Interest Coverage Range Over the Past 10 Years
Min: 11.07  Med: 16.22 Max: 30.91
Current: 11.07
11.07
30.91
Piotroski F-Score: 6
Altman Z-Score: 2.50
Beneish M-Score: -2.80
WACC vs ROIC
5.96%
7.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 16.05
NVSEF's Operating Margin % is ranked higher than
74% of the 781 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. NVSEF: 16.05 )
Ranked among companies with meaningful Operating Margin % only.
NVSEF' s Operating Margin % Range Over the Past 10 Years
Min: 16.05  Med: 20.76 Max: 22.35
Current: 16.05
16.05
22.35
Net Margin % 13.23
NVSEF's Net Margin % is ranked higher than
74% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.12 vs. NVSEF: 13.23 )
Ranked among companies with meaningful Net Margin % only.
NVSEF' s Net Margin % Range Over the Past 10 Years
Min: 13.23  Med: 18.81 Max: 35.29
Current: 13.23
13.23
35.29
ROE % 9.09
NVSEF's ROE % is ranked higher than
58% of the 803 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.08 vs. NVSEF: 9.09 )
Ranked among companies with meaningful ROE % only.
NVSEF' s ROE % Range Over the Past 10 Years
Min: 8.95  Med: 14.79 Max: 25.73
Current: 9.09
8.95
25.73
ROA % 4.94
NVSEF's ROA % is ranked higher than
56% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. NVSEF: 4.94 )
Ranked among companies with meaningful ROA % only.
NVSEF' s ROA % Range Over the Past 10 Years
Min: 4.94  Med: 8.59 Max: 16.19
Current: 4.94
4.94
16.19
ROC (Joel Greenblatt) % 49.37
NVSEF's ROC (Joel Greenblatt) % is ranked higher than
87% of the 817 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.08 vs. NVSEF: 49.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVSEF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 43.78  Med: 59.62 Max: 69.75
Current: 49.37
43.78
69.75
3-Year Revenue Growth Rate 2.90
NVSEF's 3-Year Revenue Growth Rate is ranked lower than
59% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NVSEF: 2.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVSEF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.9  Med: 2.5 Max: 12.3
Current: 2.9
-3.9
12.3
3-Year EBITDA Growth Rate -4.80
NVSEF's 3-Year EBITDA Growth Rate is ranked lower than
75% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. NVSEF: -4.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVSEF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.7  Med: 0.4 Max: 11.6
Current: -4.8
-7.7
11.6
3-Year EPS without NRI Growth Rate -4.80
NVSEF's 3-Year EPS without NRI Growth Rate is ranked lower than
68% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. NVSEF: -4.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVSEF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -7.1  Med: 3.2 Max: 82
Current: -4.8
-7.1
82
GuruFocus has detected 8 Warning Signs with Novartis AG NVSEF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVSEF's 30-Y Financials

Financials (Next Earnings Date: 2017-10-24)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NVSEF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:PFE, XSWX:ROG, NYSE:MRK, NYSE:ABBV, XPAR:SAN, XTER:BAYN, NYSE:BMY, LSE:GSK, NYSE:LLY, LSE:AZN, NYSE:JNJ, TSE:4503, TSE:4519, TSE:4578, TSE:4568, TSE:4528, HKSE:01093, MIL:REC, TSE:4151, BOM:500087 » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVS.USA,
Headquarter Location:Switzerland
Novartis AG is a part of the healthcare industry. Its main activity is to research and develop healthcare products and pharmaceuticals such as oncology medicines, generic and biosimilar medicines and eye care devices.

Novartis develops and manufactures healthcare products within four main operating segments: branded drugs, generic pharmaceuticals, eye care products, and consumer products. The company sells its products globally with the U.S. representing close to a third of total sales.

Top Ranked Articles about Novartis AG

Let’s Talk About CAR-T A quick overview of treatment and the major players in bringing promising cancer-fighting technologies to market
For those interested in staying up to date with the latest developments in biotechnology it is impossible to overlook the developments of chimeric antigen receptor therapy (CAR-T) and the potential it holds for treating cancer. The most pivotal moment came on Aug. 30 when Novartis (NVS) announced approval for Kymriah™ (tisagenlecleucel) for treating children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. Read more...
Novartis and the Future of Gene Therapy The company recently became the first to market a gene therapy for cancer
Gene therapy is now, finally, a new weapon in our arsenal against cancer partly thanks to, of all things, the HIV virus. The world’s first chimeric antigen receptor T-cell (CAR-T) treatment was approved by the Food and Drug Administration at the end of last month, a treatment developed by one Dr. Carl June at University of Pennsylvania in partnership with Novatris AG (NYSE:NVS). Read more...
Everybody Wins With GlaxoSmithKline's Latest Deal What the latest deal means for the cancer space as a whole
GlaxoSmithKline PLC (NYSE:GSK) just announced it has executed on an option that will see it license a technology developed, and proprietary to, by small-cap biotechnology stock Adaptimmune Therapeutics PLC (NASDAQ:ADAP). Read more...
John Rogers Continues to Buy Accenture, Novartis, Apache The guru purchased these stocks in the last 2 quarters
John Rogers (Trades, Portfolio) founded Ariel Investment LLC in 1983. In both the first and second quarters the guru bought shares in the following stocks: Read more...
Chris Davis Keeps Buying Intel, Ctrip.com, Novartis The guru bought these stocks in the last 2 quarters
Chris Davis (Trades, Portfolio) is the portfolio manager of Davis Financial Fund. In both the first and second quarters the guru bought shares in the following stocks: Read more...
Why Emmaus Might Have Just Made Itself Attractive to Big Pharma How the company's latest development makes it a potential takeover target
If you would have mentioned the name Emmaus Life Sciences to an investor, even one familiar with the biotechnology space, a couple of months ago, chances are the said investor would not have had any idea who you were talking about. In fact, the same probably applies today. Read more...
DURECT's Collaboration with Sandoz Clears HSR Review and is Effective
Spring Bank Pharmaceuticals' Hepatitis B Results in Context Here's a look at where the company's latest data fit into the hepatitis B space as a whole
Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) announced positive initial Phase II results for its new antiviral hepatitis B (HBV) treatment SB-9200. Shares have recorded all-time highs, up as much as 28% on the news. Read more...
Dodge & Cox Buys Express Scripts, Bristol-Myers, HP The guru's largest 1st-quarter transactions
Dodge & Cox was founded in 1930 by Van Duyn Dodge and E. Morris Cox, and it manages a portfolio of 179 stocks. During the first quarter the guru traded shares in the following companies. Read more...
DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States

Ratios

vs
industry
vs
history
PE Ratio 30.68
NVSEF's PE Ratio is ranked lower than
60% of the 570 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.41 vs. NVSEF: 30.68 )
Ranked among companies with meaningful PE Ratio only.
NVSEF' s PE Ratio Range Over the Past 10 Years
Min: 5.7  Med: 15.8 Max: 31.12
Current: 30.68
5.7
31.12
Forward PE Ratio 16.26
NVSEF's Forward PE Ratio is ranked higher than
59% of the 74 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.53 vs. NVSEF: 16.26 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 30.68
NVSEF's PE Ratio without NRI is ranked lower than
60% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.56 vs. NVSEF: 30.68 )
Ranked among companies with meaningful PE Ratio without NRI only.
NVSEF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.63  Med: 18.11 Max: 31.15
Current: 30.68
10.63
31.15
Price-to-Owner-Earnings 20.57
NVSEF's Price-to-Owner-Earnings is ranked higher than
72% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.43 vs. NVSEF: 20.57 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NVSEF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.18  Med: 15.37 Max: 21.91
Current: 20.57
7.18
21.91
PB Ratio 2.87
NVSEF's PB Ratio is ranked lower than
51% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. NVSEF: 2.87 )
Ranked among companies with meaningful PB Ratio only.
NVSEF' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 2.43 Max: 3.52
Current: 2.87
1.69
3.52
PS Ratio 4.05
NVSEF's PS Ratio is ranked lower than
60% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. NVSEF: 4.05 )
Ranked among companies with meaningful PS Ratio only.
NVSEF' s PS Ratio Range Over the Past 10 Years
Min: 1.89  Med: 3.26 Max: 5.03
Current: 4.05
1.89
5.03
Price-to-Free-Cash-Flow 20.74
NVSEF's Price-to-Free-Cash-Flow is ranked higher than
59% of the 212 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.72 vs. NVSEF: 20.74 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NVSEF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.04  Med: 16.76 Max: 26.65
Current: 20.74
7.04
26.65
Price-to-Operating-Cash-Flow 16.05
NVSEF's Price-to-Operating-Cash-Flow is ranked higher than
56% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.64 vs. NVSEF: 16.05 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NVSEF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.75  Med: 13.02 Max: 19.28
Current: 16.05
5.75
19.28
EV-to-EBIT 26.25
NVSEF's EV-to-EBIT is ranked lower than
66% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.28 vs. NVSEF: 26.25 )
Ranked among companies with meaningful EV-to-EBIT only.
NVSEF' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.55 Max: 27
Current: 26.25
8.5
27
EV-to-EBITDA 16.88
NVSEF's EV-to-EBITDA is ranked lower than
51% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.61 vs. NVSEF: 16.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVSEF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.1 Max: 18.1
Current: 16.88
7.3
18.1
EV-to-Revenue 4.41
NVSEF's EV-to-Revenue is ranked lower than
61% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.07 vs. NVSEF: 4.41 )
Ranked among companies with meaningful EV-to-Revenue only.
NVSEF' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 3.3 Max: 5.4
Current: 4.41
2.1
5.4
Shiller PE Ratio 17.29
NVSEF's Shiller PE Ratio is ranked higher than
83% of the 204 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.18 vs. NVSEF: 17.29 )
Ranked among companies with meaningful Shiller PE Ratio only.
NVSEF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.7  Med: 14.98 Max: 21.62
Current: 17.29
9.7
21.62
Current Ratio 1.01
NVSEF's Current Ratio is ranked lower than
89% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. NVSEF: 1.01 )
Ranked among companies with meaningful Current Ratio only.
NVSEF' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.38 Max: 2.83
Current: 1.01
0.83
2.83
Quick Ratio 0.75
NVSEF's Quick Ratio is ranked lower than
88% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. NVSEF: 0.75 )
Ranked among companies with meaningful Quick Ratio only.
NVSEF' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.12 Max: 2.48
Current: 0.75
0.59
2.48
Days Inventory 139.97
NVSEF's Days Inventory is ranked lower than
61% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.98 vs. NVSEF: 139.97 )
Ranked among companies with meaningful Days Inventory only.
NVSEF' s Days Inventory Range Over the Past 10 Years
Min: 117.82  Med: 150.76 Max: 183.45
Current: 139.97
117.82
183.45
Days Sales Outstanding 60.73
NVSEF's Days Sales Outstanding is ranked higher than
62% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. NVSEF: 60.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVSEF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.6 Max: 70.59
Current: 60.73
56.31
70.59
Days Payable 97.16
NVSEF's Days Payable is ranked higher than
66% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 68.69 vs. NVSEF: 97.16 )
Ranked among companies with meaningful Days Payable only.
NVSEF' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 116.45 Max: 135.35
Current: 97.16
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.18
NVSEF's Dividend Yield % is ranked higher than
89% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. NVSEF: 3.18 )
Ranked among companies with meaningful Dividend Yield % only.
NVSEF' s Dividend Yield % Range Over the Past 10 Years
Min: 1.53  Med: 3.44 Max: 5.11
Current: 3.18
1.53
5.11
Dividend Payout Ratio 0.99
NVSEF's Dividend Payout Ratio is ranked higher than
64% of the 416 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NVSEF: 0.99 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NVSEF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.4  Med: 0.64 Max: 0.99
Current: 0.99
0.4
0.99
3-Year Dividend Growth Rate 7.60
NVSEF's 3-Year Dividend Growth Rate is ranked higher than
51% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. NVSEF: 7.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NVSEF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -70.6  Med: 7.85 Max: 18.5
Current: 7.6
-70.6
18.5
Forward Dividend Yield % 3.18
NVSEF's Forward Dividend Yield % is ranked higher than
84% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. NVSEF: 3.18 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.10
NVSEF's 5-Year Yield-on-Cost % is ranked higher than
87% of the 849 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. NVSEF: 4.10 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NVSEF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.97  Med: 4.43 Max: 6.58
Current: 4.1
1.97
6.58
3-Year Average Share Buyback Ratio 0.70
NVSEF's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. NVSEF: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVSEF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: 1.05 Max: 2.4
Current: 0.7
-2.1
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 29.30
NVSEF's Price-to-Tangible-Book is ranked lower than
96% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. NVSEF: 29.30 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVSEF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.68  Med: 4.49 Max: 12455
Current: 29.3
2.68
12455
Price-to-Intrinsic-Value-Projected-FCF 1.35
NVSEF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
69% of the 306 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. NVSEF: 1.35 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NVSEF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.67  Med: 1.16 Max: 2.52
Current: 1.35
0.67
2.52
Price-to-Median-PS-Value 1.24
NVSEF's Price-to-Median-PS-Value is ranked lower than
66% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.04 vs. NVSEF: 1.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVSEF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.15 Max: 3.11
Current: 1.24
0.64
3.11
Price-to-Graham-Number 6.32
NVSEF's Price-to-Graham-Number is ranked lower than
92% of the 438 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.97 vs. NVSEF: 6.32 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NVSEF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.27  Med: 2.07 Max: 81.67
Current: 6.32
1.27
81.67
Earnings Yield (Greenblatt) % 3.81
NVSEF's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. NVSEF: 3.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVSEF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.7  Med: 6.4 Max: 11.8
Current: 3.81
3.7
11.8
Forward Rate of Return (Yacktman) % 2.79
NVSEF's Forward Rate of Return (Yacktman) % is ranked lower than
64% of the 397 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.07 vs. NVSEF: 2.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NVSEF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1  Med: 12.6 Max: 42.2
Current: 2.79
1
42.2

More Statistics

Revenue (TTM) (Mil) $49,226.00
EPS (TTM) $ 2.74
Beta0.83
Short Percentage of Float0.00%
52-Week Range $66.35 - 87.20
Shares Outstanding (Mil)2,342.90

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 49,136 51,093 54,691
EPS ($) 4.75 5.17 5.74
EPS without NRI ($) 4.75 5.17 5.74
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.80%
Dividends per Share ($) 2.82 2.95 3.18

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}